Pharmacy Times March 14, 2025
Matthew Zirwas, MD, addresses the significant financial burden associated with the medication, emphasizing the importance of pharmacists in navigating prior authorizations and access patient support programs.
In an interview with Pharmacy Times, Matthew Zirwas, MD, discusses the challenges and benefits of using ruxolitinib (Opzelura; Incyte) for atopic dermatitis and vitiligo. He addresses the significant financial burden associated with the medication, emphasizing the importance of pharmacists in navigating prior authorizations and accessing patient support programs. Zirwas also highlights the ease of patient compliance with ruxolitinib due to its rapid symptom relief, particularly for atopic dermatitis. For vitiligo, he stresses the need for patient education and ongoing communication, recommending the use of selfies to track and visualize subtle improvements, which can encourage...